Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, together with its consortium partners, today announced that it has been awarded a EUR 6.3 million Horizon 2020 EU research grant to develop an integrated approach for personalized cancer treatment. The four-year research project, ‘Liquid biopsies and IMAging for improved cancer care’ (LIMA), aims to increase the accuracy of both genetic and functional characterization of primary breast cancer and rectal cancer by combining two diagnostic technologies: advanced blood tests called liquid biopsy and Magnetic Resonance Imaging (MRI). The clinical research studies will be carried out at the University Medical CenterUniversitair Medisch Centrum Utrecht in the Netherlands, and the Institut National de la Sante et de la Recherche Medicale in France.

Source: Stilla Technologies

>> Read full article